solriamfetol

orally available, phenylalanine-derived, second-generation wake-promoting agent

Also Known As:

(2R)-2-amino-3-phenylpropyl carbamate; (R)-2-amino-3-phenylpropylcarbamate hydrochloride; ADX-N05; JZP-110; Sunosi; benzenepropanol, beta-amino-, carbamate (ester), (betaR)-; solriamfetol hydrochloride

Networked: 70 relevant articles (20 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Carter, Lawrence P: 11 articles (11/2022 - 07/2017)
2.	Black, Jed: 10 articles (01/2022 - 07/2016)
3.	Mayer, Geert: 10 articles (12/2021 - 01/2019)
4.	Chen, Dan: 9 articles (11/2022 - 01/2019)
5.	Lee, Lawrence: 9 articles (10/2021 - 01/2019)
6.	Lu, Yuan: 9 articles (01/2019 - 09/2015)
7.	Rosenberg, Russell: 8 articles (01/2022 - 09/2015)
8.	Thorpy, Michael J: 7 articles (01/2022 - 01/2019)
9.	Baladi, Michelle: 6 articles (01/2022 - 01/2020)
10.	Dauvilliers, Yves: 6 articles (01/2022 - 01/2019)

Related Diseases

1.	Narcolepsy 07/01/2017 - "In patients with narcolepsy, JZP-110 significantly improved the ability to stay awake compared with placebo, with large effect sizes using both the 40-min and 20-min censored MWT data." 05/01/2022 - "Therefore, there is a necessity to explore the efficacy of new treatments, such as solriamfetol (JZP-110), a 2019 FDA-approved drug indicated to improve wakefulness in adults with EDS associated with narcolepsy. " 11/01/2022 - "This study suggests that safety and efficacy of solriamfetol for treating EDS in narcolepsy and OSA are not affected by depression history. " 10/01/2020 - "In clinical trials, solriamfetol has shown dose-dependent improvement in wakefulness over placebo and adds another option for clinicians when treating ES in narcolepsy and OSA." 01/01/2019 - "This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy. "
2.	Sleepiness 11/01/2023 - "In such patients, solriamfetol reduced excessive sleepiness and improved wakefulness compared with placebo over 12 weeks. " 09/01/2015 - "The efficacy of JZP-110 for impaired wakefulness and excessive sleepiness was observed at 150-300 mg/day and as early as one week after initiating treatment (Clinicaltrials.gov identifier NCT01485770)." 01/01/2019 - "Coprimary endpoints (Maintenance of Wakefulness Test sleep latency and Epworth Sleepiness Scale score) were met at all solriamfetol doses (P < 0.05), with dose-dependent effects observed at Week 1 maintained over the study duration. " 01/01/2019 - "Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study." 01/01/2021 - "A dose of 150 mg solriamfetol is proved to be the appropriate and stable dose for excessive sleepiness. "
3.	Obstructive Sleep Apnea 01/01/2022 - "Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario." 01/01/2021 - "Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy." 01/01/2022 - "Placebo/solriamfetol treatment or adherence to primary obstructive sleep apnea therapy did not affect reliability. " 01/01/2020 - ": Solriamfetol improved measures of functioning, quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness. " 02/01/2023 - "NCT02806895, EudraCT 2015-003930-28: A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea. "
4.	Disorders of Excessive Somnolence (Hypersomnia) 04/01/2023 - "Given that impurities may affect the quality and safety of drug products, impurity identification and profiling is an integral part of drug quality control and is particularly important for newly developed medications such as solriamfetol, which is used to treat excessive daytime sleepiness. " 12/01/2022 - "Solriamfetol for the Management of Excessive Daytime Sleepiness." 11/01/2022 - "Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea." 01/01/2021 - "Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment." 01/01/2020 - ": Solriamfetol improved measures of functioning, quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness. "
5.	Cataplexy 05/01/2022 - "More clinical trials are needed to analyze the efficacy of solriamfetol on cataplexy. " 05/01/2022 - "We conducted this systematic review to investigate the effectiveness of solriamfetol in EDS and cataplexy, and the drug's overall safety. " 01/01/2020 - "No changes in the number of cataplexy attacks were observed for solriamfetol compared with placebo (mean ± standard deviation changes: - 3.6 ± 13.3 [combined solriamfetol] and - 3.5 ± 9.8 [placebo]). " 01/01/2020 - "For PGI-C at week 12, the mean percentage difference from placebo (95% CI) for solriamfetol 75, 150, and 300 mg in the cataplexy subgroup was 10% (- 15 to 35), 33% (9-57), and 39% (16-61), respectively (p < 0.05; 150 and 300 mg), and in the non-cataplexy subgroup was 48% (25-70), 44% (21-67), and 52% (30-73), respectively (p < 0.001; all doses), with somewhat differential treatment effects for 75 mg by cataplexy status. " 01/01/2020 - "At week 12, LS mean (95% CI) differences from placebo on ESS change from baseline for solriamfetol 75, 150, and 300 mg in the cataplexy subgroup were - 1.3 (- 3.9 to 1.3), - 3.7 (- 6.4 to - 1.1), and - 4.5 (- 7.1 to - 1.9), respectively (p < 0.01; 150 and 300 mg), and in the non-cataplexy subgroup were - 3.0 (- 5.6 to - 0.4), - 3.7 (- 6.3 to - 1.2), and - 4.9 (- 7.6 to - 2.2), respectively (p < 0.05; all doses). "

Related Drugs and Biologics

1.	Norepinephrine (Noradrenaline)
2.	pitolisant
3.	Dopamine (Intropin)
4.	Modafinil (Provigil)
5.	Sodium Oxybate (gamma Hydroxybutyrate)
6.	Methylphenidate (Ritalin)
7.	Antidepressive Agents (Antidepressants)
8.	Amphetamine (Amfetamine)
9.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Therapeutics
2.	Off-Label Use
3.	Renal Dialysis (Hemodialysis)